UPDATE: Baird Starts Fate Therapeutics (FATE) at Neutral

June 2, 2022 4:25 PM EDT
Get Alerts FATE Hot Sheet
Price: $23.83 +5.12%

Rating Summary:
    18 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 24
Join SI Premium – FREE
(Updated - June 3, 2022 6:58 AM EDT)

Baird analyst Jack Allen initiates coverage on Fate Therapeutics (NASDAQ: FATE) with a Neutral rating and a price target of $28.00.

The analyst ocmments "We are encouraged by Fate’s ability to manufacture cell therapies using iPSCs, which could have key advantages as it relates to both the production of more consistent cell therapies and lowering cost of goods. However, we are initiating with a Neutral rating as the clinical data surrounding the company’s NK cell therapies are limited at this time. Moving forward, we will continue to monitor the evolution of Fate's clinical programs and note the company plans to provide updates on all four of its programs in 2H22."

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $22.63 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird